 We now propose a pilot study of HLA-matched, related, reduced-intensity allogeneic HSCT in refractory hematologic malignancies, using an intensified EPOCH-F induction chemotherapy regimen with rituximab added for patients with CD20 malignancies EPOCH-FR. This regimen will be evaluated for toxicity and disease control before transplantation. GVHD prophylaxis will consist of a standard dual-agent regimen, cyclosporinemethotrexate; the impact of this change on hematopoietic recovery, donorrecipient chimerism, and the incidence of acute GVHD will be assessed. 